RB
ONCT

Richmond Brothers’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Richmond Brothers’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,696
Closed -$188K – 38
2024
Q2 		$188K Hold
24,696
– – 0.37% 20
2024
Q1 		$222K Sell
24,696
-6
-0% -$53 0.41% 21
2023
Q4 		$265K Hold
24,702
– – 0.46% 21
2023
Q3 		$148K Buy
24,702
+10,150
+70% +$71.5K 0.28% 22
2023
Q2 		$100K Buy
14,552
+12,634
+659% +$83.3K 0.16% 21
2023
Q1 		$30.1K Buy
+1,918
New +$37.7K 0.05% 22

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Richmond Brothers's ONCT Position: Q3 2024 in Review

Richmond Brothers sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 24,696 shares — an estimated $188K sold.

Richmond Brothers first reported a position in ONCT in Q1 2023 and held it in 6 quarters. The position peaked at $265K in Q4 2023. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.

  • Richmond Brothers reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Richmond Brothers sold 24,696 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $188K.
  • Richmond Brothers first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
  • Richmond Brothers's Oncternal Therapeutics, Inc. Common Stock position peaked at $265K in Q4 2023.
  • 23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Richmond Brothers's 13F filing for Q3 2024, filed 12 Nov 2024.